Douglas Doerfler has sold MXCT and made no open-market buys since Nov 2021

Douglas A. Doerfler is a biotechnology executive and corporate insider best known as the longtime President and Chief Executive Officer of MaxCyte, Inc. (NASDAQ: MXCT), a cell‑engineering company focused on enabling next‑generation cell therapeutics and bioprocessing applications.( He founded MaxCyte around 1998–1999 and led the company for approximately 24 years, guiding it from initial technology concept through the commercialization of its flow electroporation platform and its evolution into a publicly listed company in both Europe and the United States.( Under his leadership, MaxCyte established itself as a key partner for pharmaceutical and biotechnology firms developing cell‑based therapies.(

During his tenure as President, CEO, and director, Doerfler was active in broader industry leadership, including serving on the Board of Directors of the Biotechnology Innovation Organization (BIO).( He has also represented MaxCyte and the biotech sector in public forums, providing testimony as President and CEO of MaxCyte and presenting at major industry meetings such as the BIO International Convention.( Following his decision to retire as President and CEO effective January 1, 2024, he stepped down from MaxCyte’s Board of Directors but continues to serve as an advisor to the company.(

Written by Perplexity from public sources.